当前位置: 首页 >> 检索结果
4745. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
作者: Ital Nemet.;Limor Kliker.;Yaniv Lustig.;Neta Zuckerman.;Oran Erster.;Carmit Cohen.;Yitshak Kreiss.;Sharon Alroy-Preis.;Gili Regev-Yochay.;Ella Mendelson.;Michal Mandelboim.
来源: N Engl J Med. 2022年386卷5期492-494页 4748. Covid-19 Vaccine Effectiveness in New York State.
作者: Eli S Rosenberg.;Vajeera Dorabawila.;Delia Easton.;Ursula E Bauer.;Jessica Kumar.;Rebecca Hoen.;Dina Hoefer.;Meng Wu.;Emily Lutterloh.;Mary Beth Conroy.;Danielle Greene.;Howard A Zucker.
来源: N Engl J Med. 2022年386卷2期116-127页
Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug Administration are limited. Whether declines in effectiveness are due to waning immunity, the B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or other causes is unknown.
4749. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
作者: Barbra A Dickerman.;Hanna Gerlovin.;Arin L Madenci.;Katherine E Kurgansky.;Brian R Ferolito.;Michael J Figueroa Muñiz.;David R Gagnon.;J Michael Gaziano.;Kelly Cho.;Juan P Casas.;Miguel A Hernán.
来源: N Engl J Med. 2022年386卷2期105-115页
The messenger RNA (mRNA)-based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes across diverse populations is unknown.
4750. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
作者: Robert L Gottlieb.;Carlos E Vaca.;Roger Paredes.;Jorge Mera.;Brandon J Webb.;Gilberto Perez.;Godson Oguchi.;Pablo Ryan.;Bibi U Nielsen.;Michael Brown.;Ausberto Hidalgo.;Yessica Sachdeva.;Shilpi Mittal.;Olayemi Osiyemi.;Jacek Skarbinski.;Kavita Juneja.;Robert H Hyland.;Anu Osinusi.;Shuguang Chen.;Gregory Camus.;Mazin Abdelghany.;Santosh Davies.;Nicole Behenna-Renton.;Frank Duff.;Francisco M Marty.;Morgan J Katz.;Adit A Ginde.;Samuel M Brown.;Joshua T Schiffer.;Joshua A Hill.; .
来源: N Engl J Med. 2022年386卷4期305-315页
Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain.
4753. Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
作者: Khitam Muhsen.;Nimrod Maimon.;Ami Mizrahi.;Baruch Varticovschi.;Omri Bodenheimer.;Udi Gelbshtein.;Itamar Grotto.;Dani Cohen.;Ron Dagan.
来源: N Engl J Med. 2022年386卷4期399-401页 4758. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
作者: Angélica Jayk Bernal.;Monica M Gomes da Silva.;Dany B Musungaie.;Evgeniy Kovalchuk.;Antonio Gonzalez.;Virginia Delos Reyes.;Alejandro Martín-Quirós.;Yoseph Caraco.;Angela Williams-Diaz.;Michelle L Brown.;Jiejun Du.;Alison Pedley.;Christopher Assaid.;Julie Strizki.;Jay A Grobler.;Hala H Shamsuddin.;Robert Tipping.;Hong Wan.;Amanda Paschke.;Joan R Butterton.;Matthew G Johnson.;Carisa De Anda.; .
来源: N Engl J Med. 2022年386卷6期509-520页
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
|